A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects

被引：146

作者：

Raimundo, S ^{[1
]}

Toscano, C ^{[1
]}

Klein, K ^{[1
]}

Fischer, J ^{[1
]}

Griese, EU ^{[1
]}

Eichelbaum, M ^{[1
]}

Schwab, M ^{[1
]}

Zanger, UM ^{[1
]}

机构：

[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 76卷 / 02期

关键词：

D O I：

10.1016/j.clpt.2004.04.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Individuals with the cytochrome P450 (CYP) 2D6 intermediate metabolizer (IM) phenotype have low residual enzyme activity and compose about 10% to 15% of white populations. Their identification is clinically relevant but remains unsatisfactory because of incomplete characterization of the major allele involved, termed CYP2D6(star)41 (-1584C, R296C, S486T). Methods: To search for novel mutations, resequencing of the entire CYP2D6 gene was performed in selected individuals. Genotype-phenotype correlation analysis was done in a population sample of 308 white subjects phenotyped with sparteine and previously genotyped for all major alleles. Results: A total of 16 novel polymorphic positions were identified, of which 7 were located within 2.4 kilobases of previously uncharacterized 2D7-2D6 intergenic sequence and 9 were located within intronic regions. The novel mutation 2988G>A in intron 6 appeared to be specifically associated with the IM phenotype. Further analysis in the population sample demonstrated that 2988G>A was strongly linked to allele (star)41 but not to any other alleles including (star)1, (star)2, (star)2xN, (star)4, (star)6, (star)7, (star)8, (star)9, (star)10, and (star)35. The overall frequency of the novel polymorphism was 8.4% in the normal white population. Compared with conventionally determined (star)41, 2988G>A was shown to have improved predictivity for the IM phenotype. With 2988G>A being taken into account, alleles (star)1, (star)2, and (star)35 (-1584G, V11M, R296C, S486T) were found to be phenotypically equivalent. Conclusions: CYP2D6 genotyping can be considerably simplified by using 2988G>A as a marker for (star)41 and by omitting genotyping for the functionally equivalent alleles (star)2 and (star)35.

引用

页码：128 / 138

页数：11

共 26 条

[21]

Sachse C, 1997, AM J HUM GENET, V60, P284

[22] CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR [J].

Schaeffeler, E ;

Schwab, M ;

Eichelbaum, M ;

Zanger, UM .

HUMAN MUTATION, 2003, 22 (06) :476-485

[23] HOMOLOGOUS UNEQUAL CROSS-OVER INVOLVING A 2.8-KB DIRECT REPEAT AS A MECHANISM FOR THE GENERATION OF ALLELIC VARIANTS OF THE HUMAN CYTOCHROME-P450 CYP2D6 GENE [J].

STEEN, VM ;

MOLVEN, A ;

AARSKOG, NK ;

GULBRANDSEN, AK .

HUMAN MOLECULAR GENETICS, 1995, 4 (12) :2251-2257

[24] Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms [J].

Yu, AM ;

Kneller, BM ;

Rettie, AE ;

Haining, RL .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :1291-1300

[25] Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry [J].

Zanger, UM ;

Raimundo, S ;

Eichelbaum, M .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (01) :23-37

[26] Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6 [J].

Zanger, UM ;

Fischer, J ;

Raimundo, S ;

Stüven, T ;

Evert, BO ;

Schwab, M ;

Eichelbaum, M .

PHARMACOGENETICS, 2001, 11 (07) :573-585

← 1 2 3 →

A novel intronic mutation, 2988G&gt;A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects